In a statement released on May 7, MMJ International Holdings, MMJ BioPharma Cultivation and MMJ BioPharma Labs are urging Congress, the Trump Administration, and the American public to "demand accountability from a rogue agency whose outdated interpretation of 'public interest' obstructs legitimate medical progress".
MMJ BioPharma Labs has been granted a Schedule I Analytical Laboratory Registration by the DEA - a license that permits the handling and testing of the most tightly regulated controlled substances. This authorization confirms MMJ's compliance, secure infrastructure, and scientific capability. Despite this, the company claims that the DEA continues to withhold the complementary license MMJ needs to cultivate those same substances for FDA-approved clinical trials.
"If we're trusted to test Schedule I materials in a DEA-licensed lab," said Duane Boise, CEO of MMJ, "why are we blocked from growing the exact same materials for federally sanctioned drug development?"
"This isn't just a bad policy decision - it's a breach of public trust," said Boise. "Patients with serious neurological diseases are waiting. The science is ready. The infrastructure is ready. We're simply asking the DEA to stop standing in the way of medical progress."
For more information:
MMJ BioPharma Cultivation
www.mmjbiopharma.com